Meglumine metrizoate
Isopaque (meglumine metrizoate) is a small molecule pharmaceutical. Meglumine metrizoate was first approved as Isopaque 440 on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Calcium metrizoate
+
Meglumine metrizoate
+
Metrizoate magnesium
+
Metrizoate sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ISOPAQUE 440 | GE Healthcare | N-016847 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
963 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | 23 | 43 | 6 | 1 | 5 | 69 | |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 12 | 5 | 22 | 2 | 3 | 44 |
| Neoplasms | D009369 | C80 | 12 | 9 | 3 | 1 | 3 | 24 | |
| Human influenza | D007251 | EFO_0007328 | J11.1 | 4 | 7 | 4 | 3 | 1 | 18 |
| Acne vulgaris | D000152 | EFO_0003894 | L70 | 4 | 1 | 5 | 6 | 1 | 16 |
| Cutaneous leishmaniasis | D016773 | B55.1 | 1 | 6 | 7 | 1 | 2 | 15 | |
| Hyperphosphatemia | D054559 | HP_0002905 | — | 1 | 4 | 3 | 6 | 13 | |
| Postoperative pain | D010149 | G89.18 | — | 2 | 1 | 4 | 4 | 11 | |
| Malaria | D008288 | EFO_0001068 | B54 | 6 | 1 | — | 2 | — | 8 |
| Covid-19 | D000086382 | U07.1 | 2 | 3 | — | 2 | 2 | 8 |
Show 68 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | D46 | 51 | 97 | 8 | — | 14 | 149 | |
| Leukemia | D007938 | C95 | 37 | 83 | 13 | — | 10 | 122 | |
| Lymphoma | D008223 | C85.9 | 27 | 61 | 4 | — | 15 | 96 | |
| Myeloid leukemia acute | D015470 | C92.0 | 42 | 58 | 5 | — | 5 | 95 | |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 29 | 43 | 4 | — | 4 | 72 | |
| Non-hodgkin lymphoma | D008228 | C85.9 | 20 | 36 | 1 | — | 5 | 54 | |
| Multiple myeloma | D009101 | C90.0 | 19 | 31 | 2 | — | 6 | 52 | |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | 10 | 33 | 2 | — | 3 | 43 | |
| Hodgkin disease | D006689 | C81 | 13 | 26 | 4 | — | 4 | 41 | |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | 12 | 21 | 2 | — | 3 | 33 |
Show 85 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Plasma cell neoplasms | D054219 | 14 | 28 | — | — | 6 | 44 | ||
| Melanoma | D008545 | 12 | 17 | — | — | — | 27 | ||
| Burkitt lymphoma | D002051 | C83.7 | 6 | 14 | — | — | 3 | 21 | |
| B-cell lymphoma marginal zone | D018442 | C88.4 | 7 | 11 | — | — | 4 | 20 | |
| Primary myelofibrosis | D055728 | D47.4 | 5 | 11 | — | — | 2 | 18 | |
| Large-cell lymphoma anaplastic | D017728 | C84.6 | 5 | 13 | — | — | 3 | 18 | |
| Large-cell lymphoma immunoblastic | D016400 | 5 | 11 | — | — | 3 | 17 | ||
| Healthy volunteers/patients | — | 12 | 1 | — | — | 4 | 16 | ||
| Lymphomatoid granulomatosis | D008230 | C83.8 | 4 | 11 | — | — | 3 | 16 | |
| Extranodal nk-t-cell lymphoma | D054391 | C86.0 | 4 | 10 | — | — | 3 | 15 |
Show 121 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Plasmacytoma | D010954 | C90.3 | 1 | — | — | — | 1 | 2 | |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | 1 | 2 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | 1 | 2 |
| Rickets | D012279 | EFO_0005583 | E55.0 | 1 | — | — | — | 1 | 2 |
| Hepatic insufficiency | D048550 | 2 | — | — | — | — | 2 | ||
| Gram-positive bacterial infections | D016908 | 2 | — | — | — | — | 2 | ||
| Dengue | D003715 | A90 | 2 | — | — | — | — | 2 | |
| Depression | D003863 | F33.9 | 2 | — | — | — | — | 2 | |
| Beta-thalassemia | D017086 | Orphanet_848 | D56.1 | 1 | — | — | — | — | 1 |
| Plantar fasciitis | D036981 | EFO_1001909 | M72.2 | 1 | — | — | — | — | 1 |
Show 26 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sars-cov-2 | D000086402 | — | — | — | — | 2 | 2 | ||
| Sinus floor augmentation | D059546 | — | — | — | — | 2 | 2 | ||
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 2 | 2 |
| Papillomaviridae | D027383 | — | — | — | — | 1 | 1 | ||
| Dermatitis | D003872 | HP_0011123 | L30.9 | — | — | — | — | 1 | 1 |
| Sexual behavior | D012725 | — | — | — | — | 1 | 1 | ||
| Hypertrophic cicatrix | D017439 | L91.0 | — | — | — | — | 1 | 1 | |
| Cicatrix | D002921 | HP_0100699 | L90.5 | — | — | — | — | 1 | 1 |
| Keloid | D007627 | EFO_0004212 | L91.0 | — | — | — | — | 1 | 1 |
| Newborn respiratory distress syndrome | D012127 | P22 | — | — | — | — | 1 | 1 |
Show 44 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | MEGLUMINE METRIZOATE |
| INN | — |
| Description | Isopaque (meglumine metrizoate) is a small molecule pharmaceutical. Meglumine metrizoate was first approved as Isopaque 440 on 1982-01-01. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)Nc1c(I)c(C(=O)O)c(I)c(N(C)C(C)=O)c1I.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO |
Identifiers
| PDB | — |
| CAS-ID | 7241-11-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200353 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,656 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
8,687 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more